Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925555 | 0.81 | RAB9A (0.35) | OPRL1OPRM1 | |
| SCHEMBL22833645 | 0.72 | SMN1; SMN2 (0.37) | OPRL1OPRM1KDM4ESMN1; SMN2BRD4 | |
| SCHEMBL24879759 | 0.66 | PIK3CD (0.50) | KDM4ESMN1; SMN2 | |
| SCHEMBL22833643 | 0.66 | LMNA (0.39) | OPRL1KDM4ESMN1; SMN2BRD4KAT2B | |
| SCHEMBL13488612 | 0.66 | BRD4 (0.41) | OPRL1KDM4ESMN1; SMN2BRD4PPARG | |
| SCHEMBL11724781 | 0.65 | KDM4E (0.42) | KDM4ESMN1; SMN2KAT2BLMNAALDH1A1 | |
| SCHEMBL14086671 | 0.65 | PPARG (0.44) | KDM4ESMN1; SMN2PPARGKAT2BLMNA | |
| SCHEMBL27320156 | 0.65 | KDM4E (0.36) | KDM4ESMN1; SMN2BRD4PPARGKAT2B | |
| SCHEMBL14170610 | 0.64 | ACE (0.45) | OPRL1OPRM1OPRK1 | |
| SCHEMBL28657636 | 0.64 | LMNA (0.37) | KDM4ESMN1; SMN2BRD4KAT2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | OPRL1 1506/4885OPRM1 1039/4885KDM4E 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.